Thermo Fisher Scientific Inc. $TMO Stock Position Raised by Klingman & Associates LLC

Klingman & Associates LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,665 shares of the medical research company’s stock after purchasing an additional 120 shares during the period. Klingman & Associates LLC’s holdings in Thermo Fisher Scientific were worth $675,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of TMO. Phoenix Financial Ltd. grew its holdings in Thermo Fisher Scientific by 25.5% in the 2nd quarter. Phoenix Financial Ltd. now owns 4,887 shares of the medical research company’s stock worth $2,000,000 after buying an additional 992 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its position in shares of Thermo Fisher Scientific by 0.7% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 772,643 shares of the medical research company’s stock valued at $317,498,000 after purchasing an additional 5,425 shares in the last quarter. Journey Advisory Group LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter valued at $2,611,000. Canvas Wealth Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 170.2% in the 2nd quarter. Canvas Wealth Advisors LLC now owns 1,394 shares of the medical research company’s stock valued at $565,000 after purchasing an additional 878 shares during the period. Finally, Lyell Wealth Management LP increased its position in shares of Thermo Fisher Scientific by 4.3% in the second quarter. Lyell Wealth Management LP now owns 32,114 shares of the medical research company’s stock worth $13,021,000 after acquiring an additional 1,333 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In other news, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock valued at $14,182,963 over the last ninety days. 0.33% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

TMO has been the subject of several research analyst reports. Raymond James Financial reissued an “outperform” rating and issued a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. JPMorgan Chase & Co. upped their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. Scotiabank upgraded Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target on the stock in a report on Friday, July 11th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Finally, Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, October 12th. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $589.10.

Thermo Fisher Scientific Stock Up 0.9%

Shares of TMO opened at $544.02 on Tuesday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The firm has a market capitalization of $205.43 billion, a P/E ratio of 31.46, a P/E/G ratio of 2.93 and a beta of 0.77. The company has a 50-day simple moving average of $497.37 and a 200-day simple moving average of $449.73. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the previous year, the company posted $5.37 earnings per share. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.